Venetoclax is a BCL-2 inhibitor, recently approved by the Food and Drug Administration (FDA) in combination with HMA to treat de novo AML patients unfit for intensive chemotherapy, where BCL-2 anti-apoptotic protein is usually upregulated and associated with poor prognosis and resistance to chemotherapy [28]. Here, BCL2 is linked to acute myeloid leukemia.